beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis

ग्रंथसूची विवरण
मुख्य लेखकों:	Parry, A, Corkill, R, Blamire, A, Palace, J, Narayanan, S, Arnold, D, Styles, P, Matthews, P
स्वरूप:	Journal article
प्रकाशित:	2002

समान संसाधन

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
द्वारा: Parry, A, और अन्य
प्रकाशित: (2003)

Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis.
द्वारा: Lee, M, और अन्य
प्रकाशित: (2000)

Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy.
द्वारा: Blamire, A, और अन्य
प्रकाशित: (2007)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
द्वारा: Sørensen, P, और अन्य
प्रकाशित: (2010)

Axonal loss in the optic nerve and tract in multiple sclerosis
द्वारा: Esiri, M, और अन्य
प्रकाशित: (2000)

Beta-interferons in multiple sclerosis
द्वारा: Aggarwal Sourabh, और अन्य
प्रकाशित: (2010-01-01)

Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.
द्वारा: Evangelou, N, और अन्य
प्रकाशित: (2000)

Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis.
द्वारा: Reddy, H, और अन्य
प्रकाशित: (2000)

Interferon beta treatment of multiple sclerosis.
द्वारा: Markovitz, D
प्रकाशित: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
द्वारा: Mohamed Rayen Ganouni, और अन्य
प्रकाशित: (2023-10-01)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
द्वारा: Sibley, W, और अन्य
प्रकाशित: (1994)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
द्वारा: Clerico, M, और अन्य
प्रकाशित: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
द्वारा: Clerico, M, और अन्य
प्रकाशित: (2008)

Treatment of multiple sclerosis with interferon beta-1 b.
द्वारा: Abdul-Ahad, A, और अन्य
प्रकाशित: (1997)

Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis.
द्वारा: Evangelou, N, और अन्य
प्रकाशित: (2000)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
द्वारा: V. Yu. Lizhdvoy, और अन्य
प्रकाशित: (2016-07-01)

Association between cortical metabolite levels and clinical manifestations of migrainous aura: an MR-spectroscopy study.
द्वारा: Schulz, U, और अन्य
प्रकाशित: (2007)

Interictal cellular energy reserves in migraineurs with prolonged aura or coma and migrainous stroke: A brain P-31-MR-spectroscopy study
द्वारा: Schulz, U, और अन्य
प्रकाशित: (2003)

31P-and 1H-NMR spectroscopy: A dose-response-relationship between metabolite levels and severity of aura symptoms
द्वारा: Schulz, U, और अन्य
प्रकाशित: (2006)

Treatment of multiple sclerosis with interferon beta-1b - Reply
द्वारा: Sibley, W, और अन्य
प्रकाशित: (1997)

Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.
द्वारा: Parry, A, और अन्य
प्रकाशित: (2003)

Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis.
द्वारा: Cader, S, और अन्य
प्रकाशित: (2007)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
द्वारा: Mahe J, और अन्य
प्रकाशित: (2013-08-01)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
द्वारा: Elmazny A, और अन्य
प्रकाशित: (2020-03-01)

White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis.
द्वारा: Parry, A, और अन्य
प्रकाशित: (2002)

A cost-utility analysis of interferon beta for multiple sclerosis.
द्वारा: Parkin, और अन्य
प्रकाशित: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
द्वारा: Masoud Mohammad Malekzadeh, और अन्य
प्रकाशित: (2020-06-01)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
द्वारा: Clerico, M, और अन्य
प्रकाशित: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
द्वारा: Clerico, M, और अन्य
प्रकाशित: (2006)

Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy
द्वारा: A. D. Kukushkina, और अन्य
प्रकाशित: (2024-08-01)

Slowing of axonal regeneration is correlated with increased axonal viscosity during aging
द्वारा: Heidemann Steven R, और अन्य
प्रकाशित: (2010-10-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
द्वारा: C. Carbonelli, और अन्य
प्रकाशित: (2015-12-01)

Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis
द्वारा: A.L. Guerrero, और अन्य
प्रकाशित: (2011-01-01)

Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
द्वारा: V. Byrnes, और अन्य
प्रकाशित: (2006-01-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
द्वारा: Dian HE, और अन्य
प्रकाशित: (2014-09-01)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
द्वारा: De Caro Maria, और अन्य
प्रकाशित: (2006-12-01)

Beta-interferons in multiple sclerosis: A single center experience in India
द्वारा: Gupta Salil, और अन्य
प्रकाशित: (2010-01-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
द्वारा: Ivanović Jovana, और अन्य
प्रकाशित: (2019-01-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
द्वारा: Cocco E, और अन्य
प्रकाशित: (2015-05-01)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
द्वारा: Castrop F, और अन्य
प्रकाशित: (2013-09-01)